Figures & data
Table 1. Summary of studies of outer membrane vesicle vaccines against Neisseria meningitidis.
Table 2. Summary of human clinical trials of serogroup B meningococcal vaccines with recombinant proteins.
Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH14, 195–207 (1991). Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine13, 821–829 (1995). Bjune G, Høiby EA, Grønnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338, 1093–1096 (1991). de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340, 1074–1078 (1992). Tappero JW, Lagos R, Ballesteros AM, Plikaytis B et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999). Peeters CC, Rumke HC, Sundermann LC et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine14, 1009–1015 (1996). Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol.38, 413–418 (2009). Caron F, du Chatelet IP, Leroy JP et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect. Dis.11(6), 455–463 (2011). van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine25, 2491–2496 (2007). Gorringe AR, Taylor S, Brookes C et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin. Vaccine Immunol.16, 1113–1120 (2009). Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine29, 1413–1420 (2011). Miller E, Pollard AJ, Borrow R et al. Safety and immunogenicity of Novartis meningococcal serogroup B vaccine after three doses administered in infancy. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID), Graz, Austria, 13–17 May 2008. Snape M, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J.29(11), 71–79 (2010). Vesikari T et al. Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine in healthy infants at 2, 4 and 6 months of age. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010. Esposito S et al. Tolerability of a three-dose schedule of investigational, multicomponent meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Canada, 11–16 September 2010. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroup A, C, W-135 and Y in adult who are at increased risk for occupational exposure to meningococcal isolated. Clin. Vaccine Immunol.18(3), 483–486 (2011). Nissen MD, Marshall KS, Richmond P et al. A randomized, placebo-controlled, double-blind, Phase I trial of ascending dose of meningococcal group B rLP2086 vaccine. Presented at: 26th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). Graz, Austria, 13–17 May 2008. Richmond P, Marshall H, Sheldon E et al. Safety and immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Albert, Canada, 11–16 September 2010.